‘FABIFLU’: GLENMARK'S COVID-19 DRUG GETS DGCI APPROVAL

Highlights

• FabiFlu is the first oral Favipiravir-approved medication for the treatment of coronavirus

• Favipiravir was approved in Japan in the year 2014 and shown clinical improvement of up to 88 percent in mild to moderate COVID-19 cases

• Glenmark will work closely with the government and medical community said Glenn Saldanha, Chairman & MD of Glenmark Pharmaceuticals

On Saturday....